MMR（0d），HPV（1m），HPV（7m） — Competitive Intelligence Brief

MMR（0d），HPV（1m），HPV（7m） (MMR（0d），HPV（1m），HPV（7m）) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology / Infectious Disease.

marketed vaccine Immunology / Infectious Disease Biologic

Target snapshot

MMR（0d），HPV（1m），HPV（7m） (MMR（0d），HPV（1m），HPV（7m）) — Zhejiang Provincial Center for Disease Control and Prevention. This is a vaccination schedule combining MMR (measles, mumps, rubella) and HPV (human papillomavirus) vaccines to provide immunization against these viral infections.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MMR（0d），HPV（1m），HPV（7m） TARGET	MMR（0d），HPV（1m），HPV（7m）	Zhejiang Provincial Center for Disease Control and Prevention	marketed	vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Recombinant Human Papillomavirus Nonavalent Vaccine	Recombinant Human Papillomavirus Nonavalent Vaccine	National Cancer Institute (NCI)	marketed	Recombinant vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58
Recombinant influenza vaccines	Recombinant influenza vaccines	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Vaccine	Influenza hemagglutinin (HA) and neuraminidase (NA) antigens
Recombinant influenza hemagglutinin	Recombinant influenza hemagglutinin	Vaxine Pty Ltd	marketed	Recombinant protein vaccine	Influenza hemagglutinin
recombinant adjuvanted zoster vaccine	recombinant adjuvanted zoster vaccine	Wuerzburg University Hospital	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

1. Pfizer · 20 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
3. GlaxoSmithKline · 12 drugs in this class
4. Merck Sharp & Dohme LLC · 12 drugs in this class
5. Centers for Disease Control and Prevention · 9 drugs in this class
6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
10. Sinovac Biotech Co., Ltd · 4 drugs in this class